Analysis artefacts of the INS-IGF2 fusion transcript by Rasmus Wernersson et al.
Wernersson et al. BMC Molecular Biol  (2015) 16:13 
DOI 10.1186/s12867-015-0042-8
RESEARCH ARTICLE
Analysis artefacts of the INS-IGF2 fusion 
transcript
Rasmus Wernersson1,2*, Thomas Frogne3†, Claude Rescan3†, Lena Hansson1†, Christine Bruun3, 
Mads Grønborg3, Jan Nygaard Jensen3* and Ole Dragsbæk Madsen3*
Abstract 
Background: In gene expression analysis, overlapping genes, splice variants, and fusion transcripts are potential 
sources of data analysis artefacts, depending on how the observed intensity is assigned to one, or more genes. We 
here exemplify this by an in-depth analysis of the INS-IGF2 fusion transcript, which has recently been reported to be 
among the highest expressed transcripts in human pancreatic beta cells and its protein indicated as a novel autoanti-
gen in Type 1 Diabetes.
Results: Through RNA sequencing and variant specific qPCR analyses we demonstrate that the true abundance 
of INS-IGF2 is >20,000 fold lower than INS in human beta cells, and we suggest an explanation to the nature of the 
artefacts which have previously led to overestimation of the gene expression level in selected studies. We reinvesti-
gated the previous reported findings of detection of INS-IGF2 using antibodies both in Western blotting and immu-
nohistochemistry. We found that the one available commercial antibody (BO1P) raised against recombinant INS-IGF2 
show strong cross-reaction to native proinsulin, and we did not detect INS-IGF2 protein in the human beta cell line 
EndoC-βH1. Furthermore, using highly sensitive proteomics analysis we could not demonstrate INS-IGF2 protein in 
samples of human islets nor in EndoC-βH1.
Conclusions: Sequence features, such as fusion transcripts spanning multiple genes can lead to unexpected results 
in gene expression analysis, and care must be taken in generating and interpreting the results. For the specific case 
of INS-IGF2 we conclude that the abundance of the fusion transcript/protein is exceedingly lower than previously 
reported, and that current immuno-reagents available for detecting INS-IGF2 protein have a strong cross-reaction to 
native human proinsulin. Finally, we were unable to detect INS-IGF2 protein by proteomics analysis.
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Background
Gene expression analysis artefacts
As part of our research on pancreatic beta cell biology, 
our group has been investigating the transcripts origi-
nating from the insulin loci using both microarrays and 
RNA-sequencing platforms. On several occasions we 
have noticed issues with the way overlapping transcripts 
are handled in gene expression analysis pipelines, and 
this sparked the interest for looking further into the 
underlying reasons for the problems. Our initial observa-
tions were as follows:
In DNA microarray analysis different results will be 
obtained for the genes in the genomic region around INS 
(Ensembl: ENSG00000254647) depending on the map-
ping scheme used. In extreme cases INS itself will dis-
appear from the analysis and all its signal would instead 
be mapped to INS-IGF2 (Ensembl: ENSG00000129965). 
The reason for this artefact turned out to be that certain 
widely used enhanced remapping schemes for Affym-
etrix probes (including the popular BrainArray CDF 
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files) are targeting the longest transcript in the region. In 
most cases this will not cause an issue, since all the tran-
scripts variants will in the end be mapped to the same 
underlying gene. However, in the case of INS the issue 
is that a fusion transcript, INS-IGF2, is spanning the 
entire region (see Fig. 1 and Additional file 1: Figure S1), 
including both insulin exons as well as part of the adja-
cent IGF2-locus. This will lead to all signal in the region 
being mapped to INS-IGF2 and that INS will “disappear” 
from the analysis, and in certain cases so would IGF2 
(Ensembl: ENSG00000167244). This will happen even 
if there are no probes targeting the unique part of the 
fusion transcript.
For RNA sequencing analysis a related problem is 
encountered. The individual reads will typically be 
mapped to a set of transcripts from the organism in ques-
tion, and will be assigned multiple times to transcripts 
sharing sequences. In most cases this is the desired 
behaviour, and will be a way to handle splicing variants 
of a given gene (and a more thorough analysis of exon/
exon junctions can be investigated). However, in the case 
of transcripts spanning several genes, there is a risk that 
the signal from one gene bleeds into the overlapping 
transcript, and this may not be apparent when the results 
are reported.
With this in mind, we decided to re-investigate the 
observation by Nica et  al. [1] that the INS-IGF2 fusion 
transcript was found to be the second most abundant 
mRNA in human beta cells, an observation that has gen-
erated much interest in the beta cell biology field since 
INS-IGF2 has previously been annotated to be translated 
[2] and moreover, recently proposed as a novel autoanti-
gen in Type 1 Diabetes (T1D) [3].
Case background: beta cell biology
The pancreatic beta cell is a key component in regulat-
ing blood glucose homeostasis as it represents our sole 
source of insulin, which is required for peripheral tissues 
to internalize and utilize glucose as an energy source. 
Lack of adequate functional beta cell mass leading to rel-
ative insulin insufficiency is the common denominator of 
all forms of diabetes. T1D is characterized by an absolute 
loss of beta cells as a result of autoimmune destruction. 
Type 2 diabetes (T2D) is where a relative beta cell insuffi-
ciency results from failure of compensatory upregulation 
of insulin production capacity in response to increas-
ing peripheral insulin resistance. Therefore much effort 
in, both preventive and curative, diabetes research has 
aimed at understanding the molecular networks, both at 
the level of transcriptional and translational regulation of 
Fig. 1 RNA sequencing read depth in the INS/IGF2 genomic region. Plot of the genomic region of chromosome 11 around the INS and IGF2 loci 
(2150,000–2190,000; genomic assembly: GRCh37/hg19) with probesets from the Affymetix HG-U133A array and the main transcript variants of INS, 
INS-IGF2 and IGF2 indicated below the plot. All shown transcripts are encoded on the antisense strand (as indicated by the direction of the arrows 
in the introns)—for an overview of all known transcript variants, please see Additional file 1: Figure S1 (panel A). The y-axis shows the read depth of 
the RNA sequencing study from Nica et al. [1]—notice that read depth was capped at 8,000 (data shown for beta cell dataset #6—the same pattern 
was observed for all other data sets). From the plot it is clearly seen that few reads maps to the INS-IGF2 exons in the 2170000 area (middle of the 
plot) and almost all signal assigned to INS-IGF2 by Nica et al. [1] originates from the first coding exon which is shared with INS (right hand side of the 
plot). All positional information on this plot is from ENSEMBL v.75.
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genes controlling development and at the function and 
survival of the pancreatic beta cell. Recent advancements 
in the ability to purify single cell types from the Islet of 
Langerhans combined with omics’ approaches have led 
to detailed information of the transcriptomic environ-
ment of beta cells.
Gene-knockouts, and animal models, in particular tar-
geting transcription factors combined with genome-wide 
association studies, have in the past decade provided us 
with a comprehensive map of genes and loci that may 
cause or contribute to diabetes, and it is evident that bet-
ter understanding of molecular control(s) of functional 
beta cell mass will be key to design strategies to defeat 
diabetes.
All classical studies, not surprisingly, report a very high 
abundance of insulin mRNA, and insulin represents one 
of the most abundant cell specific mRNA’s known in our 
body. It was therefore surprising to realize that the sec-
ond most abundant beta cell mRNA, recently reported in 
FACS purified human beta cells [1], was encoding INS-
IGF2. Values comparable to glucagon mRNA levels in 
purified human alpha cells was reported for INS-IGF2 
suggesting that a putative and highly abundant beta cell 
protein could have been overlooked. Moreover, recent 
studies suggested that INS-IGF2 could be yet another 




In our reanalysis of the RNA sequencing data from Nica 
et  al. [1] we did not map the reads to transcripts but 
rather investigated an unbiased mapping of the reads to 
the genomic region on chromosome 11 containing the 
INS, IGF2 and INS-IGF2 transcripts. By visual inspec-
tion of the distribution of the reads (Fig. 1), it is clearly 
observed that the regions specific to INS-IGF2 are 
lowly expressed, whereas the INS specific exons are (as 
expected in beta cells) highly expressed.
Both coding exons of INS being expressed at the same 
order of magnitude is a clear indication that (a) most 
reads mapped to the exon that is shared by both INS 
and INS-IGF2 belong to the INS-001 transcript, and 
(b) the perceived high expression of the INS-IGF2 tran-
script is due to the read count being assigned to both 
genes, where the difference in level is due to the different 
lengths of the two genes.
The data analysis artefact is especially pronounced in 
this case, since INS in itself constitutes a large part of 
the transcript pool in beta cells. In our own experiments 
using the human beta cell line EndoC-βH1 we observe 
the same trends, both with RNA sequencing and micro-
array analysis (unpublished, data not shown).
Both RNA sequencing and DNA micro-arrays are 
measuring sequence fragments, therefore we decided to 
take the analysis one step further and devised a qPCR 
strategy based on splice-form specific primers in order 
to provide a more direct measurement of the individual 
unfragmented mRNA species, in both EndoC-βH1 cells 
and human islets. In both cases the observations are the 
same; the INS-IGF2 fusion transcript is expressed at 
a level >20,000 fold lower than the INS transcript (see 
Table 1), and is hence barely detectable.
Proteome analysis
To finalise our conclusion that INS-IGF2 expression lev-
els have been vastly overestimated, we investigated the 
abundance of the INS-IGF2 fusion protein using a strat-
egy involving both immunochemical detection and mass 
spectrometry.
For the immuno-chemical work we used the only 
commercially available antibody (BO1P) raised against 
Table 1 qPCR analysis of INS-IGF2, INS and IGF2
Relative expression of INS-IGF2, INS and IGF2 determined by qPCR for EndoC-βH1 cells and human islets. All mRNAs were analysed in 3 independent preparations, 
each in technical duplicate and the average of each duplicate is shown for each preparation (prep). GAPDH was used as input control. It is clear that INS-IGF2 is 
expressed at very low levels compared to Insulin, i.e. in the order of >20,000 fold less in human islets and 40,000 fold less in the human beta cell line EndoC-βH1.
Cell type Gene cDNA input (ng) Ct values GAPDH normalized 
exp. Rel. To INS
Prep1 Prep2 Prep 3 Mean GAPDH norm
Human islets INS 0.05 20.5 18.9 20.4 19.9 −6.3 1
Human islets INS-IGF2 0.05 No Ct 33.3 34.8 34.8 8.1 0.000046
Human islets IGF2 0.05 32.8 32.7 31.3 32.3 6 0.000194
Human islets GAPDH 0.05 26.9 27 24.9 26.2 0 –
EndoC-βH1 INS 5 14.8 14.3 14.4 14.5 −3 1
EndoC-βH1 INS-IGF2 5 29.9 30.8 28.3 29.7 12.2 0.000072
EndoC-βH1 IGF2 5 18.3 19.2 18.2 18.6 1.1 0.059678
EndoC-βH1 GAPDH 5 17.2 18.2 17.1 17.5 0 –
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full-length INS-IGF2. This spans the preproinsulin sig-
nal-peptide, the entire B-chain of insulin and the first 8 
amino acids of the C-peptide (which then continues into 
sequences that are unique for the INS-IGF2 protein—
and thus not shared by IGF2 itself, see Fig. 2). As can be 
seen from Fig. 3, the commercial antibody readily detects 
the expression of recombinant INS-IFG2 in transduced 
HEK-293 cells and in transduced EndoC-βH1 cells. It is 
important to note that this antibody (also used by Kanat-
suna et al. [3]) show strong cross-reaction to proinsulin 
in EndoC-βH1 cells whereas it only detects a band with 
the expected MW of INS-IGF2 in transduced cells (Fig. 3, 
panel a). We thus observe that the protein level of INS-
IGF2 in EndoC-βH1 is below detection limit by Western 
blotting.
The control-antibody GS-9A8 (Madsen, Frank et  al. 
[4]), a well characterized proinsulin-specific antibody 
binding a linear epitope spanning the B-C junction 
(Fig.  2) show full cross-reaction to recombinant INS-
IGF2 (Fig. 3, panel a upper)—as would be expected with 
the intact proinsulin-B-C junction preserved in the INS-
IGF2 protein (Fig. 2).
From band intensities in Western blotting experi-
ments we conclude that the commercial polyclonal anti-
body BOA1 has higher affinity towards INS-IGF2 than 
for proinsulin and yet it fails to detect any INS-IGF2-
like immunoreactivity in native human EndoC-βH1. In 
transduced EndoC-βH1 the expression of INS-IGF2 is 
much lower than proinsulin. Yet a weaker band is read-
ily detected by BOA1 but completely absent in native 
human EndoC-βH1. Similarly, the GS-9A8 antibody hav-
ing a presumed equal high affinity for both proinsulin and 
INS-IGF2 completely fails to detect an INS-IGF2 band in 
native human EndoC-βH1. In summary, these data are in 
line with the low levels of transcript we see in the human 
beta cell line, EndoC-βH1, which again raise the question 
do the protein exist?
We do observe that the antibody raised against INS-
IGF2 (BO1P) indeed stain human beta cells on section of 
human pancreas (Fig. 3, panel b), but we cannot deduce if 
this is only due to the expected cross-reaction to proinsu-
lin. In fact, the two antibodies, GS-9A8 and BO1P display 
very similar staining of proinsulin-like immuno-reactivity 
in human beta cells (Fig. 3, Panel b).
In order to further investigate the abundance of the 
INS-IGF2 protein level we conducted a comprehen-
sive analysis of both EndoC-βH1 cells as well as isolated 
human islets using high-resolution mass spectrometry. 
Human islets were digested by trypsin and fraction-
ated by either hydrophilic interaction chromatography 
(HILIC) or strong cation exchange (SCX) chromatogra-
phy prior to reverse phase liquid chromatography tan-
dem mass spectrometry (LC–MS). Our 2D fractionation 
method combined with high resolution MS allowed us 
to identify a total of 8,441 distinct human islet proteins. 
As expected, we were able to identify human insulin with 
five unique peptides and a high Mascot protein score 
(>500).
Moreover, we did identify proteins known to be 
expressed at a notoriously low level including transcrip-
tion factors (e.g. FOS-B, NAC-2, SOX4 and SOX5), 
nuclear receptors (e.g. NR2F6 and NR5A2) and nuclear 
receptor coactivators (e.g. NCOA2, NCOA4 and 
NCOA6). However, even though we identified close to 
8,500 proteins in our analysis we were not able to iden-
tify peptides specific to the INS-IGF2 protein in the sam-
ples. This indicates that INS-IGF2 is at most expressed in 
exceedingly low abundance in human islets.
In the proteomic analysis of the human beta cell line 
EndoC-βH1 we again identified a large number of dis-
tinct proteins (close to 7,000) including insulin and low 
abundant proteins but again, we were not able to identify 
peptides specific to the INS-IGF2 protein.
However, the caveat one has to keep in mind with MS-
based proteomics experiments is the fact that absence 
of evidence is not evidence of absence. Therefore, in 
order to ensure that the INS-IFG2 protein could indeed 
be identified by our proteomics approach, HEK cells 
transduced with either INS-IGF2 or a control construct 
were subjected to the same analysis. Both samples were 
Fig. 2 Protein level sequence comparison between unprocessed preproinsulin and the INS-IGF2 fusion protein. The epitope of the proinsulin spe-
cific monoclonal antibody GS-9A8 is indicated [4]. The BO1P antibody also used in this study was raised against the full length INS-IGF2 protein.
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analysed by LC–MS and peptides specific for INS-IGF2 
were readily observed only in the sample transduced with 
the INS-IGF2 construct. The missing evidence of INS-
IGF2 protein in human islets and in EndoC-βH1 cells is 
therefore not related to our LC–MS approach.
In summary, based on sensitive proteomic and immu-
nologic detection methods using adequate positive con-
trols, we conclude that INS-IGF2 protein is expressed in 
exceedingly low abundance in normal human islet beta 
cells as well as in EndoC-βH1. This finding correlates 
well with the exceedingly low expression level of the INS-
IGF2 mRNA.
Discussion
We see the significance of the observations presented 
here to be two-fold:
1. To increase the awareness of the type of data inter-
pretation artefacts fusion transcripts (or other over-
lapping sequence features) can inflict upon gene 
expression analysis for both RNA sequencing and 
micro-array experiments. In our opinion, the main 
problem is that the analysis artefacts can go unno-
ticed, which can lead to the publication of misleading 
results and wasted efforts in follow-up experimental 
work. In addition to the issue with the abundance of 
INS-IGF2 being over-reported, we have seen several 
published micro-array studies, where INS wrongly 
was reported to be missing on the array (with com-
ments along the line of “…Ins gene was excluded from 
ranking as it was not annotated in our Affymetrix 
chip…” [5]).
a b
Fig. 3 Immunoblot analysis and immunostaining of human pancreas. a Western blots investigating the presence of proinsulin-immunoreactivity 
(using antibody GS-9A8, upper panel) and INS-IGF2 fusion protein immunoreactivity (using antibody BO1P, lower panel) in the human beta cell line 
EndoC-βH1 and HEK, non transduced, GFP transduced or INS-IGF2 transduced. Endogenous proinsulin is marked with (Asterisk) and INS-IGF2 with 
(filled circle). Notice that INS-IGF2 is only reliably detected in cells transduced with INS-IGF2 construct. We titrated the levels of transduced HEK293 
cell extract to give comparable band intensities on EndoC-βH1 proinsulin and HEK293-INS-IGF2 (panel a upper: GS-9A8 which has assumed identical 
affinities to the two proteins). INS-IGF2 transduction of EndoC-βH1 leads to relative lower expression of INS-IGF2-protein compared to proinsulin 
(panel a upper comparing the two bands in lane INS-IGF2-EndoC-βH1). This low-level expression of INS-IGF2 protein in transduced EndoC-βH1 is 
readily detected using the INS-IGF2 antibody while untransduced cells are completely negative (panel a lower). Thus we conclude that the expres-
sion of INS-IGF2 protein in EndoC-βH1 is below detection limits of this assay. b Immunoreactivity for INS-IGF2 (green) and glucagon (red) (top panel), 
and for proinsulin (green) and glucagon (red) (bottom panel) on adjacent sections of human pancreas. Scale bar 100 µM.
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The problem with over-reporting of overlapping tran-
scripts may actually be more prevalent than immediately 
evident, as most cases are likely to be much less extreme 
than the case of insulin and INS-IGF2 in beta cells and 
thus go unnoticed. In fact, there are in total 459 human 
protein-coding transcripts that share exons in Ensembl 
77, that could potentially be affected by the same misas-
signment as reported here.
On a more fundamental level, we recognize that biol-
ogy is complicated and it is difficult to devise one true 
interpretation of the transcripts. Furthermore, a compli-
cating factor is that as more and more transcripts variants 
are sequenced and deposited into the genomic databases 
(e.g. from large scale efforts such as the ENCODE pro-
ject [6]), the risk of encountering this kind of problems is 
therefore likely to increase.
Part of this problem is, in essence, that these variants 
will carry the same weight in the analysis, even if some 
of them are exceedingly rare. On a more technical note, 
there is also the issue of what is classified as a gene in its 
own right as opposed to a transcript variant. In the case 
of INS-IGF2 part of the problem is that it’s listed as an 
independent gene and not as a splice variant of INS, as 
the analysis artefact could otherwise be side-stepped by 
aggregating the signal at the gene level.
While devising a “perfect” solution to the problem 
with overlapping genes is far from trivial, following an 
approach of listing which other transcripts may contrib-
ute to the signal of any given gene, could help to bring 
potential problems out in the open.
Lastly, it should be mentioned that several recent pub-
lications of islet transcriptomics data do not report on 
a faulty INS-IGF2 expression as they specifically han-
dle this issue. Eizirik et  al. [7] used the Flux Capacitor 
approach [8] to specifically handle the problem of reads 
mapping to exonic regions shared by multiple transcripts. 
Moran et  al. [9] addressed the multiple transcript map-
ping issue by applying custom parameters in the RNA 
sequencing pipeline. The issue of handling exons from 
multiple transcripts is highly dependant on the software 
tool used, including its version and default parameters. 
For example, for users of the TopHat2 software package 
it should be noted, that the default settings for handling 
multiple transcript mapping was changed around Sep-
tember 2012 [10].
2. In the more specific case of INS-IGF2 it is important 
to avoid a chase for an elusive transcript for the many 
groups of scientists working with beta cells and islet 
biology. However, the big question remains on how 
important this transcript is? And does it indeed lead 
to the production of a novel beta cell specific protein? 
We show that the INS-IGF2 antibody as well as our 
proinsulin-specific antibody recognize an expected 
band of MW 22,000 in INS-IGF2 transduced cells 
(Hek293 and EndoC-βH1), as well as the native pro-
insulin band from the human beta cell line. The work 
of Kanatsuna et al. [3] concludes that INS-IGF2 repre-
sents a novel autoantigen in T1D, as they use in vitro 
translated/labeled INS-IGF2 to detect specific autoan-
tibodies in T1D patients. However, “pre-proinsulin” 
autoantibodies would possibly also cross-react effec-
tively in this assay, and such autoantibodies are well 
known in T1D. As an example, we show that proinsu-
lin-B/C junction specific antibody fully cross-reacts to 
INS-IGF2. More specific reagents, such as antibodies 
raised against the unique c-terminal fragment of the 
predicted INS-IGF2 protein, are required in order to 
detect the protein specifically by immunocytochemi-
cal techniques.
Finally, our data failed to demonstrate the existence of 
the INS-IGF2 mRNA and protein in EndoC-βH1 cells. 
This was further supported by lack of detection of the 
protein by proteomics analysis, both in human islets and 
the beta cell line.
Conclusions
Overlapping sequence features are problematic to 
handle in expression analysis pipelines. This chal-
lenge potentially leads to situations were some vari-
ants appears to be much higher expressed than data can 
support, or in the extreme case to completely mask out 
other genes in the vicinity. A large part of the problem 
is the “black box” nature of the gene expression analysis 
pipeline in the eyes of researchers not experts in bioin-
formatics, and that such errors may therefore go unno-
ticed. While the underlying mapping issue is far from 
trivial to solve, we suggest that by bringing the prob-
lem out in the open (e.g. by listing other factors con-
tributing to the signal of a given gene), it will be easier 
to flag potential problems with a given data set, and to 
help avoid over-, or underestimation of gene expression 
levels.
Our in-depth analysis concludes that INS-IGF2 abun-
dance is >20,000 times lower or undetectable at the level 
of mRNA and protein, respectively, compared to previ-
ous reported findings in human beta cells.
Finally, we suggest that pre-proinsulin antibodies (T1D 
autoantibodies) will also cross-react to recombinant INS-
IGF2 protein, as exemplified by a proinsulin-B-C junc-
tion specific monoclonal antibody, GS9A8.
In conclusion, we suggest that more specific antibody 
reagents (towards against INS-IGF2 unique epitopes) 
need to be developed to facilitate and support investi-
gations into whether INS-IGF2 fusion protein actually 
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might be induced to elicit an autoantigen response in 
T1D.
Methods
Reanalysis of RNA sequencing data
For the re-analysis of the human Islet of Langerhans RNA 
sequencing data from Nica et al. [1], data was downloaded 
from the European Genome-phenome Archive [11] (acces-
sion: EGAS00001000442) as processed BAM files [12].
The BAM files follow the original analysis performed 
by Nica et al. [1]: briefly, the transcript-to-genome map-
ping was done using assembly version GRCh37/hg19 
from February 2009 and GENCODE annotation v10 [13], 
which corresponds to Ensembl [14] v65. They further 
used BWA, Burrows-Wheeler Aligner [15], and filtered 
the alignments for correct orientation of the mapped 
mate pairs with a maximum insert size of 500 kb, and a 
minimum mapping quality score of 10.
In our re-analysis the processed BAM files were 
sorted and indexed and the relevant genomics region, 
chr11:2103768-2222439 (CGRh37/hg19 coordinates), 
was retrieved as Sequence Alignment/Map (SAM)-files 
via samtools [12]. Finally the read depth were calculated 
via samtools (v 0.1.19) and plotted using R (v. 3.0.2) [16]—
we here observed that the read depth had been capped at 
8,000. Exon/Intron coordinates for INS, IGF2 and INS-
IGF2 transcripts were obtained from ENSEMBL [14] ver-
sion 75 (also CGRh37/hg19 coordinates). See Additional 
file 1: Figure S1 for an in-depth overview of transcripts.
Primer design
DNA sequences from the following transcripts were 
downloaded from ENSEMBL v. 75 [14]: INS-IGF2-001 
(Ensembl: ENST00000397270), INS-001 (Ensembl: 
ENST00000381330), IGF2-001 (Ensembl: ENST000 
00416167). For primers uniquely targeting INS and INS-
IGF2 coding exons the primer placement strategy shown in 
Additional file 1: Figure S1(panel B) was used, and following 
the verification of the unique parts of the transcripts using 
global pairwise alignment the primer sets listed below were 
designed. For the IGF2 coding exons there are no overlaps 
with other genes (see Fig. 1 and Additional file 1: Figure S1 
panel A), and the probes were trivial to design.
Primerset 1 (INS specific), Forward: GCAGGTGG 
AGCTGGGC, Reverse: GGAGGAGAGGGACAAAGC 
TG. Primerset 2 (INS-IGF2 specific), Forward: CTACC 
TAGTGTGCGGGGAA, Reverse: ATTGTTCCACAA 
TGCCACGC. Primerset 3 (IGF2 specific), Forward: 
GATGCTGGTGCTTCTCACCT, Reverse: CAGACG 
AACTGGAGGGTGTC. For normalization of cDNA 
input we used GAPDH, Forward: AGGGCTGCTTTTA 
ACTCTGGT, Reverse: CCCCACTTGATTTTGGAGG 
GA. Primers were synthesized by Eurofins.
qPCR
Quantitative RT PCR was carried out by standard meth-
ods. Briefly, RNA was purified with RNeasy (Qiagen) 
and checked on a Nanodrop instrument. All OD260/280 
was ~2. The cDNA was made from 0.5 µg RNA in 20 µl 
iSCRIPT (Roche) reaction. For qPCR 2.5  µl of 10× 
(EndoC-βH1 cells) or 1,000× (Human islets) diluted 
cDNA was analysed with specific primers (see Table  1) 
and Brilliant II SYBR green mastermix (Agilent) using 
a Stratagene 3000p instrument. All PCR products were 
verified by melting curve analysis.
Cell lines
The following cell lines were used in the study. 
EndoC-βH1 Human pancreatic beta cell line 
(EndoC-βH1) [17]. The cells were grown as described 
in ref [17]. HEK293 Human embryonic kidney cell line 
(ATCC CRL-1573). The HEK293 cells were grown in 
DMEM with 10% FBS and 1% P/S.
Human pancreatic islets
Human islets were obtained via Prodo Laboratories 
Inc., CA, USA. Human pancreases were procured from 
cadaveric donors after written informed research con-
sent was provided by donor relatives. All experiments 
were performed in agreement with national legislation 
and institutional ethical rules. Upon arrival, the islets 
were cultured in CMRL1066 with 5.6  mM glucose sup-
plemented with 10% FCS, 2 mM l-Glutamine, 100 units/
ml Penicillin and 100 μg/ml streptomycin at 37°C, under 
95% air/5% CO2.
Human islet donor data: 3 donors, 1 female, 2 males; 
age, mean 34 years (range 30–38); BMI, mean 31.5 (range 
28.5–33.1); purity, mean 90% (range 85–95); viability, 
mean 94.7 (range 94–95%). None of the donors were 
diagnosed with diabetes.
Transduction
The INS-IGF2 cDNA sequence was obtained from Gen-
Bank [18] (accession id: NM_001042376.2) and the cor-
responding DNA was synthesized and inserted into a 
lentivirus vector (Gentarget Inc.). Lentivirus was pro-
duced in HEK293 cells and purified into PBS by ultracen-
trifugation. The MOI was 10 for EndoC-βH1 cells and 2 
for HEK293 cells. Selection was done with puromycin for 
1–3 weeks. As control we used the same backbone vector 
with a GFP cDNA insert.
Immunohistochemistry
Human pancreas paraffin sections (Zyagen) were 
dewaxed and rehydrated to double-distilled H2O. Sec-
tions were microwave treated for 15  min in Tris-EGTA 
buffer (pH 9.0) and were allowed to cool for 30 min and 
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rinsed in double-distilled H2O. Slides were blocked with 
TNB blocking buffer (Perkin Elmer) for 30 min, followed 
by incubation with the primary antibody guinea pig anti 
Glucagon (1:500; Linco) in combination with the mouse 
monoclonal anti proinsulin clone GS9A8 (1:100; Devel-
opmental Studies Hybridoma Bank), or the mouse poly-
clonal anti INS-IGF2 (1:100; BO1P Abnova) diluted in 
TNB o.n at room temperature. Three washes in PBS were 
then followed by incubation with fluorescent labelled 
secondary antibodies (Cy2 or Cy3 conjugated donkey 
anti guinea pig and anti rabbit IgG (1:400; Jackson Immu-
noResearch)) and DAPI diluted in TNB and three washes 
in PBS before mounting. Images were acquired using 
confocal microscopy (Zeiss LSM 510).
Western blot
Cultured HEK293 or EndoC-βH1 cells were harvested 
in Cell Extraction Buffer (Life Technologies) freshly sup-
plemented with Complete Protease Inhibitor Cocktail 
(Roche). Samples were run on 12% NuPAGE SDS gels, 
under reducing conditions in MES-SDS buffer (Invit-
rogen) and then transferred on PVDF membrane for 
chemiluminescent Western blot. Anti-proinsulin and 
INS-IGF2 antibodies have been used at 1:1,000 dilu-
tion, monoclonal anti Beta actin-peroxidase (Sigma) at 
1:25,000. Secondary antibody goat anti mouse IgG (Santa 
Cruz Biotechnology) was diluted 1:2,000.
Mass spectrometry
Human islets or EndoC-βH1 cells were lysed in 0.5% 
RapiGest (Waters, Milford, MA, USA) dissolved in 
50  mM ammonium bicarbonate. The islets were sub-
sequently reduced in DTT (10  mM) and alkylated with 
45  mM chloroacetamide. The sample was digested with 
trypsin (1:50 w/w) O.N. at 37 degrees. To precipitate the 
RapiGest (Waters, Milford, MA, USA) 10% TFA was 
added to a final concentration of 0.5%. The peptides were 
centrifuged for 20  min at room temperature and puri-
fied in a SepPak (50 mg) cartridge (Waters, Milford, MA, 
USA). The peptides were eluted with 50% acetonitrile and 
lyophilized. For HILIC fractionation, the peptides were 
dissolved in 4 ul buffer A (0.1% TFA) and 36 ul buffer B 
(98% acetonitrile, 0.1% TFA). The peptides were fraction-
ated using a gradient of 55  min (95–60% B). The frac-
tionation was done using an Agilent uHPLC 1290 system 
(Agilent Technologies, Santa Clara, USA) For SCX frac-
tionation, the column (StageTips with 3 M Empore SCX 
disks, 3 M Empore, MN, USA) was conditioned with (1) 
100% acetonitrile, (2) 50% acetonitrile pH4.0, (3) 50% 
acetonitrile pH 11, (4) 40% acetonitrile with 0.1% TFA. 
The peptides were loaded in 40% acetonitrile with 0.1% 
TFA and subsequently step eluted using a buffer con-
taining 20  mM acetic acid, 20  mM boric acid, 20  mM 
phosphoric acid, 50% acetonitrile with pH adjusted to 4.0; 
4.5; 5.0; 6.5; 7.5; 11.0, respectively. Peptides from HILIC 
and SCX fractionation were analysed by LC–MS using an 
Easy-nLC 1000 system coupled to a Q-Exactive Orbitrap 
mass spectrometer (Thermo Fisher Scientific, Bremen, 
Germany). The peptides were separated on a 90  min 
gradient (8–40% acetonitrile in 0.1% formic acid) on a 
reverse-phase column (1.9 µm beads, Dr Maisch GmbH, 
Ammerbach, Germany). The raw data was searched using 
the Mascot search engine in Proteome Discoverer v1.4 
(Thermo Scientific, Bremen, Germany) with a peptide 
false discovery rate of less than 1%, which was estimated 
on the number of reverse hits. Carbamidomethylation 
and oxidation of methionine were specified as variable 
modifications.
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